drugset / Trial / NCT02446704

Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

NCT02446704

Phase 1/2 Unknown 66 enrolled Zofia Piotrowska AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is evaluating the combination of olaparib and temozolomide as a possible treatment for Small Cell Lung Cancer.

Timeline

Start
2015-10-13
Primary completion
2022-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule Oral
Subject Temozolomide Small molecule Oral